Filing Details

Accession Number:
0001179110-21-001566
Form Type:
4
Zero Holdings:
No
Publication Time:
2021-02-10 21:12:44
Reporting Period:
2021-02-08
Accepted Time:
2021-02-10 21:12:44
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1709401 Rubius Therapeutics Inc. RUBY () 4
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1445826 R David Epstein C/O Rubius Therapeutics, Inc.
399 Binney Street, Suite 300
Cambridge MA 02139
Yes No No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Disposition 2021-02-08 89,233 $14.88 4,726,220 No 4 S Direct
Common Stock Disposition 2021-02-09 2,100 $14.83 4,724,120 No 4 S Direct
Common Stock Disposition 2021-02-10 7,404 $14.79 4,716,716 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 S Direct
No 4 S Direct
No 4 S Direct
Footnotes
  1. The sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person.
  2. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $14.75 to $15.05, inclusive. The reporting person undertakes to provide to Rubius Therapeutics, Inc., any security holder of Rubius Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.
  3. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $14.75 to $14.90, inclusive. The reporting person undertakes to provide to Rubius Therapeutics, Inc., any security holder of Rubius Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.
  4. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $14.75 to $14.87, inclusive. The reporting person undertakes to provide to Rubius Therapeutics, Inc., any security holder of Rubius Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.